PAVmed Inc (PAVM)
PAVmed Inc. is a healthcare equipment and supplies company listed on NASDAQ under the ticker PAVM. The company develops and commercializes products aimed at addressing unmet medical needs in the United States. Its lead offerings include CarpX, a patented single-use minimally invasive surgical device for carpal tunnel syndrome, as well as EsoCheck, a diagnostic cell-collection device used to help detect esophageal precancer in at-risk patients, and EsoGuard, a DNA assay performed on cells collected with EsoCheck. PAVmed’s pipeline also includes EsoCure for dysplastic Barrett’s esophagus, PortIO, an implantable intraosseous vascular access device, and the Veris cancer care platform. Founded in 2014 and based in New York, New York, the company changed its name from PAXmed Inc. in April 2015.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-PAVM
|
$7.09
|
25.0% Upside
|
Undervalued
|
$36
|
534.9% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 14, 2026
|
-1.4x
|
1.1x
|
477.5x
|
41.451 M
|
3.987 M
|
35.7%
|
72.6%
|
-8.4
|
—
|
22.1%
|
